<p>Stempoint Capital LP 在第二季度购买了 Cidara Therapeutics, Inc.（NASDAQ:CDTX - 免费报告）的一项新股份，根据其最近向美国证券交易委员会（SEC）提交的文件。该基金购买了 266,774 股该生物技术公司的股票，价值约为 12,995,000 美元。Cidara Therapeutics 占 Stempoint Capital LP 投资组合的 4.2%，使其成为该基金第八大持仓。到最近报告期末，Stempoint Capital LP 拥有约 1.05% 的 Cidara Therapeutics。</p>
<p>获取 <strong>Cidara Therapeutics</strong> 警报：</p>
<ul>
<li>默克为一种可能改变一切的流感药物支付了 92 亿美元</li>
</ul>
<p>其他一些机构投资者最近也增加或减少了对该股票的持股。Amalgamated Bank 在第二季度以 28,000 美元的估值收购了 Cidara Therapeutics 的新股份。Trifecta Capital Advisors LLC 在第二季度以约 49,000 美元的价值购买了 Cidara Therapeutics 的新股份。Legal &amp; General Group Plc 在第二季度以约 73,000 美元的价值收购了 Cidara Therapeutics 的新股份。Ameritas Investment Partners Inc. 在第二季度以约 83,000 美元的价值收购了 Cidara Therapeutics 的新股份。最后，新泽西州警察和消防员退休系统在第二季度以约 184,000 美元的价值购买了 Cidara Therapeutics 的新股份。35.82% 的股票由机构投资者和对冲基金持有。</p>
<h2>内部买卖</h2>
<p>在其他消息中，内部人士 Nicole Negar Davarpanah 于 9 月 11 日星期四出售了 474 股公司的股票。该股票以平均价格 62.86 美元出售，总价值为 29,795.64 美元。交易后，内部人士直接持有 31,418 股公司的股票，价值 1,974,935.48 美元。此次交易使其持仓减少了 1.49%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。公司内部人士持有公司股票的 7.64%。</p>
<h2>分析师评级调整</h2>
<ul>
<li>生物技术催化剂警报：NKTR、CDTX 和 WGS 大幅上涨</li>
</ul>
<p>一些分析师最近对该股票发表了看法。Needham &amp; Company LLC 在 11 月 14 日星期五的报告中将 Cidara Therapeutics 的股票评级从 “买入” 下调至 “持有”。华尔街禅在 11 月 8 日星期六的研究报告中将 Cidara Therapeutics 的评级从 “持有” 下调至 “卖出”。WBB Securities 在 10 月 9 日星期四的研究报告中将 Cidara Therapeutics 的目标价格从 123.00 美元上调至 199.00 美元，并给予该股票 “强烈买入” 评级。JMP Securities 在 10 月 3 日星期五设定了 Cidara Therapeutics 的 173.00 美元价格目标，并给予公司 “市场表现优于大盘” 评级。最后，HC Wainwright 在 11 月 14 日星期五的报告中将 Cidara Therapeutics 的评级从 “买入” 下调至 “中性”。一位研究分析师对该股票给予了 “强烈买入” 评级，四位分析师给予 “买入” 评级，六位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，平均目标价格为 156.11 美元。</p>
<p><strong>获取我们对 Cidara Therapeutics 的最新分析</strong></p>
<h2>Cidara Therapeutics 价格表现</h2>
<p>CDTX 股票在星期三开盘价为 220.29 美元。该股票的市值为 69.3 亿美元，市盈率为 -18.70，贝塔值为 1.46。Cidara Therapeutics, Inc. 的 52 周低点为 15.22 美元，52 周高点为 221.20 美元。该公司的 50 日移动平均价格为 145.12 美元，200 日移动平均价格为 85.96 美元。</p>
<p>Cidara Therapeutics（NASDAQ:CDTX - 获取免费报告）最近于 11 月 6 日星期四发布了其财报。这家生物技术公司报告的每股收益（EPS）为 -1.43 美元，低于分析师一致预期的 -1.19 美元，差距为 -0.24 美元。研究分析师预计 Cidara Therapeutics, Inc. 本年度将发布 -8.74 的每股收益。</p>
<h2>Cidara Therapeutics 公司简介</h2>
<p>（免费报告）</p>
<p>Cidara Therapeutics, Inc. 是一家生物技术公司，专注于为面临癌症和其他严重疾病的患者开发靶向疗法。该公司的产品包括 rezafungin 乙酸盐，这是一种新型分子，属于抗真菌药物的 echinocandin 类，用于治疗和预防侵袭性真菌感染，包括念珠菌血症和侵袭性念珠菌病，这些真菌感染与高死亡率相关。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Cidara Therapeutics 更好</li>
<li>股息之王宝洁在财报后疲软中值得买入</li>
<li>内部人士正在出售这三只股票——原因在这里</li>
<li>股票股息削减发生，你准备好了吗？</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>能源和石油股票解析</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年前爆炸性增长</li>
</ul>
<p><strong>想看看其他对冲基金持有 CDTX 的情况吗？</strong> 访问 HoldingsChannel.com 获取 Cidara Therapeutics, Inc.（NASDAQ:CDTX - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0RUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0RUWA"/></p>
<p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Cidara Therapeutics 吗？</h2>
<p>在考虑 Cidara Therapeutics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在买入，以便在更广泛的市场注意到之前……而 Cidara Therapeutics 并不在名单上。</p>
<p>虽然 Cidara Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CDTX

<p>Stempoint Capital LP 收购了 266,774 股 Cidara Therapeutics，价值 12,995,000 美元，占其投资组合的 4.2%。分析师对 CDTX 的评级不一，包括强烈买入、买入、持有和卖出。该股票开盘价为 220.29 美元，市值为 69.3 亿美元。Cidara 专注于严重疾病的治疗，包括抗真菌治疗</p>

<p>Stempoint Capital LP bought a new stake in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The fund bought 266,774 shares of the biotechnology company's stock, valued at approximately $12,995,000. Cidara Therapeutics makes up 4.2% of Stempoint Capital LP's portfolio, making the stock its 8th largest position. Stempoint Capital LP owned about 1.05% of Cidara Therapeutics at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Stempoint Capital LP 在第二季度购买了 Cidara Therapeutics, Inc.（NASDAQ:CDTX - 免费报告）的一项新股份，根据其最近向美国证券交易委员会（SEC）提交的文件。该基金购买了 266,774 股该生物技术公司的股票，价值约为 12,995,000 美元。Cidara Therapeutics 占 Stempoint Capital LP 投资组合的 4.2%，使其成为该基金第八大持仓。到最近报告期末，Stempoint Capital LP 拥有约 1.05% 的 Cidara Therapeutics。</p>
</div><p>Get <strong>Cidara Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cidara Therapeutics</strong> 警报：</p>
</div><ul>
<li>Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything</li>
</ul>
<div class="lb-trans"><ul>
<li>默克为一种可能改变一切的流感药物支付了 92 亿美元</li>
</ul>
</div><p>A number of other institutional investors also recently added to or reduced their stakes in the stock. Amalgamated Bank acquired a new stake in shares of Cidara Therapeutics in the second quarter valued at $28,000. Trifecta Capital Advisors LLC bought a new stake in Cidara Therapeutics during the 2nd quarter worth about $49,000. Legal &amp; General Group Plc acquired a new stake in Cidara Therapeutics in the 2nd quarter valued at about $73,000. Ameritas Investment Partners Inc. acquired a new stake in Cidara Therapeutics in the 2nd quarter valued at about $83,000. Finally, Police &amp; Firemen s Retirement System of New Jersey bought a new position in shares of Cidara Therapeutics in the second quarter worth about $184,000. 35.82% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也增加或减少了对该股票的持股。Amalgamated Bank 在第二季度以 28,000 美元的估值收购了 Cidara Therapeutics 的新股份。Trifecta Capital Advisors LLC 在第二季度以约 49,000 美元的价值购买了 Cidara Therapeutics 的新股份。Legal &amp; General Group Plc 在第二季度以约 73,000 美元的价值收购了 Cidara Therapeutics 的新股份。Ameritas Investment Partners Inc. 在第二季度以约 83,000 美元的价值收购了 Cidara Therapeutics 的新股份。最后，新泽西州警察和消防员退休系统在第二季度以约 184,000 美元的价值购买了 Cidara Therapeutics 的新股份。35.82% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, insider Nicole Negar Davarpanah sold 474 shares of the business's stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $62.86, for a total value of $29,795.64. Following the transaction, the insider directly owned 31,418 shares of the company's stock, valued at $1,974,935.48. The trade was a 1.49% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Company insiders own 7.64% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，内部人士 Nicole Negar Davarpanah 于 9 月 11 日星期四出售了 474 股公司的股票。该股票以平均价格 62.86 美元出售，总价值为 29,795.64 美元。交易后，内部人士直接持有 31,418 股公司的股票，价值 1,974,935.48 美元。此次交易使其持仓减少了 1.49%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。公司内部人士持有公司股票的 7.64%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><ul>
<li>Biotech Catalyst Alert: NKTR, CDTX &amp; WGS Rallying With Big Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>生物技术催化剂警报：NKTR、CDTX 和 WGS 大幅上涨</li>
</ul>
</div><p>A number of analysts recently weighed in on the stock. Needham &amp; Company LLC lowered shares of Cidara Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, November 14th. Wall Street Zen lowered Cidara Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 8th. WBB Securities boosted their target price on Cidara Therapeutics from $123.00 to $199.00 and gave the stock a &#34;strong-buy&#34; rating in a research report on Thursday, October 9th. JMP Securities set a $173.00 price target on Cidara Therapeutics and gave the company a &#34;market outperform&#34; rating in a research note on Friday, October 3rd. Finally, HC Wainwright cut Cidara Therapeutics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a report on Friday, November 14th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and an average target price of $156.11.</p>
<div class="lb-trans"><p>一些分析师最近对该股票发表了看法。Needham &amp; Company LLC 在 11 月 14 日星期五的报告中将 Cidara Therapeutics 的股票评级从 “买入” 下调至 “持有”。华尔街禅在 11 月 8 日星期六的研究报告中将 Cidara Therapeutics 的评级从 “持有” 下调至 “卖出”。WBB Securities 在 10 月 9 日星期四的研究报告中将 Cidara Therapeutics 的目标价格从 123.00 美元上调至 199.00 美元，并给予该股票 “强烈买入” 评级。JMP Securities 在 10 月 3 日星期五设定了 Cidara Therapeutics 的 173.00 美元价格目标，并给予公司 “市场表现优于大盘” 评级。最后，HC Wainwright 在 11 月 14 日星期五的报告中将 Cidara Therapeutics 的评级从 “买入” 下调至 “中性”。一位研究分析师对该股票给予了 “强烈买入” 评级，四位分析师给予 “买入” 评级，六位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，平均目标价格为 156.11 美元。</p>
</div><p><strong>Get Our Latest Analysis on Cidara Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Cidara Therapeutics 的最新分析</strong></p>
</div><h2>Cidara Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Cidara Therapeutics 价格表现</h2>
</div><p>CDTX stock opened at $220.29 on Wednesday. The stock has a market capitalization of $6.93 billion, a price-to-earnings ratio of -18.70 and a beta of 1.46. Cidara Therapeutics, Inc. has a fifty-two week low of $15.22 and a fifty-two week high of $221.20. The business's fifty day moving average price is $145.12 and its two-hundred day moving average price is $85.96.</p>
<div class="lb-trans"><p>CDTX 股票在星期三开盘价为 220.29 美元。该股票的市值为 69.3 亿美元，市盈率为 -18.70，贝塔值为 1.46。Cidara Therapeutics, Inc. 的 52 周低点为 15.22 美元，52 周高点为 221.20 美元。该公司的 50 日移动平均价格为 145.12 美元，200 日移动平均价格为 85.96 美元。</p>
</div><p>Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) last released its earnings results on Thursday, November 6th. The biotechnology company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.24). Research analysts expect that Cidara Therapeutics, Inc. will post -8.74 EPS for the current year.</p>
<div class="lb-trans"><p>Cidara Therapeutics（NASDAQ:CDTX - 获取免费报告）最近于 11 月 6 日星期四发布了其财报。这家生物技术公司报告的每股收益（EPS）为 -1.43 美元，低于分析师一致预期的 -1.19 美元，差距为 -0.24 美元。研究分析师预计 Cidara Therapeutics, Inc. 本年度将发布 -8.74 的每股收益。</p>
</div><h2>Cidara Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Cidara Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.</p>
<div class="lb-trans"><p>Cidara Therapeutics, Inc. 是一家生物技术公司，专注于为面临癌症和其他严重疾病的患者开发靶向疗法。该公司的产品包括 rezafungin 乙酸盐，这是一种新型分子，属于抗真菌药物的 echinocandin 类，用于治疗和预防侵袭性真菌感染，包括念珠菌血症和侵袭性念珠菌病，这些真菌感染与高死亡率相关。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Cidara Therapeutics</li>
<li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness</li>
<li>Insiders Are Selling These 3 Stocks—Here’s Why</li>
<li>Stock Dividend Cuts Happen Are You Ready?</li>
<li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li>
<li>Energy and Oil Stocks Explained</li>
<li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Cidara Therapeutics 更好</li>
<li>股息之王宝洁在财报后疲软中值得买入</li>
<li>内部人士正在出售这三只股票——原因在这里</li>
<li>股票股息削减发生，你准备好了吗？</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>能源和石油股票解析</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年前爆炸性增长</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CDTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 CDTX 的情况吗？</strong> 访问 HoldingsChannel.com 获取 Cidara Therapeutics, Inc.（NASDAQ:CDTX - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0RUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CDTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cidara Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cidara Therapeutics 吗？</h2>
</div><p>Before you consider Cidara Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Cidara Therapeutics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cidara Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在买入，以便在更广泛的市场注意到之前……而 Cidara Therapeutics 并不在名单上。</p>
</div><p>While Cidara Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cidara Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Stempoint Capital LP 在 Cidara Therapeutics, Inc. $CDTX 中建立头寸